Table 1 Comparison of clinical features between different groups.
From: Elevated serum CA72-4 as a novel diagnostic biomarker for acute gout flares
Group | Healthy controls | Gout-no-flare | Gout-flare | P value |
|---|---|---|---|---|
Case (male/female) | 309/6 | 281/5 | 245/4 | 0.964 |
Age (years) | 51.2 ± 9.2 | 51.4 ± 8.1 | 50.7 ± 7.6 | 0.962 |
Gout duration (years) | – | 7.7 ± 2.9 | 8.5 ± 3.7 | 0.321 |
Smoking (N/Y) | 179/136 | 160/126 | 133/116 | 0.710 |
Drinking (N/Y) | 171/144 | 159/127 | 137/112 | 0.949 |
Tophi | – | 1.5 ± 0.8 | 1.3 ± 0.8 | 0.295 |
Type 2 diabetes (N/Y) | 168/147 | 157/129 | 133/116 | 0.915 |
Hypertension (N/Y) | 161/154 | 154/132 | 130/119 | 0.797 |
Cardiac disease (N/Y) | 299/16 | 274/12 | 238/11 | 0.866 |
BMI (kg/m 2) | 24.7 ± 2.4 | 24.7 ± 1.9 | 25.0 ± 2.1 | 0.630 |
HbA1c (%) | 6.3 ± 1.7 | 5.9 ± 2.0 | 6.2 ± 2.5 | 0.392 |
TC (mmol/L) | 4.8 ± 0.6 | 4.9 ± 0.6 | 4.7 ± 1.0 | 0.590 |
LDL-C (mmol/L) | 2.6 ± 0.7 | 2.6 ± 0.9 | 2.5 ± 1.0 | 0.940 |
HDL-C (mmol/L) | 1.4 ± 0.4 | 1.4 ± 0.4 | 1.3 ± 0.5 | 0.406 |
ALT (IU/L) | 23 ± 4 | 23 ± 4 | 23 ± 2 | 0.361 |
AST (IU/L) | 21 ± 5 | 21 ± 5 | 22 ± 4 | 0.597 |
eGFR [ml/(min·1.73m2)] | 110.0 ± 27.5 | 105.9 ± 28.5 | 109.0 ± 41.6 | 0.754 |
sUA (umol/L) | 428(400–468) | 426(398–465) | 416(377–455) | < 0.01 |
CRP (mg/L) | 4.4(2.6–5.8) | 4.3(2.6–6.2) | 14.2(9.8–17.8) | < 0.01 |
CEA (ng/mL) | 2.4(1.6–3.5) | 2.4(1.5–3.3) | 2.5(1.5–3.5) | 0.639 |
CA12-5 (U/mL) | 12.9(8.9–16.8) | 13.0(10.1–16.1) | 12.9(9.8–16.8) | 0.711 |
CA19-9 (U/mL) | 14.3(10.2–19.3) | 13.0(9.3–18.3) | 14.2(10.4–18.8) | 0.326 |
CA72-4 (U/mL) | 3.1(2.5–3.8) | 3.9(3.0-6.2) | 22.0(16.7–43.2) | < 0.01 |
